中科院纳米生物效应与安全性重点实验室
纳米技术论坛 (NS Forum No. 175)
第175期学术报告会通知

报告人：Dr.Jing Zou
题  目：Nano-technology mediated targeted inner ear imaging and drug delivery
时　间：2011年10月17日（星期一） 上午 10: 00
地  点：国家纳米科学中心 南楼二层会议室

摘 要：
The inner and outer hair cells as well as peripheral processes of the cocholear nerve are exposed to the endolymph and Cortis fluid. The functioning of these elements depends on the carefully controlled metabolism and ion homeostasis, which are maintained by the biological barriers of the inner ear. Any change of these barriers tends to disrupt ion homeostasis and metabolism of the inner ear, and leads to hearing loss and balance disorder. Meanwhile, these barriers prevent from passage of medication to the inner ear delivered either systemically or topically. Uptodate diagnosis of inner ear diseases is mainly based on case history plus electrophysioogical examination, which has the disadvantage of lacking morphological visualization and is often not very sensitive. Developments in contrast agent-enhanced MRI and nanomedicine are making revolution in the diagnosis and treatment of inner ear diseases. Gadolinium-enhanced MRI demonstrated origin and communication of the perilymph, functional change in blood-endolymph and blood-perilymph barriers, and severity of the endolymphatic hydrops. Pathway and dynamics in topical inner ear drug delivery through the middle ear cavity are depictured with gadolinium-enhanced MRI. Using gadolinium as a tracer, theory of drug pathway from the middle ear to the inner ear was subverted and more advanced trans-tympanic drug delivery technique. The current techniques including cannula infusion, a Silverstein MicroWick device, and transtympanic injection will give way to targetable microlitter administration using micrometer level cannulation, which follows development direction of the future medicine. Advancements in nanomedicine promote development of inner ear disease diagnosis towards more accurate targets and finally to specific molecular diagnosis. Nanopharmaceutics reduces degradation of the treatment agents and enhances passage of the medicine across the inner ear biological barriers, and achieves targeted drug delivery in the inner ear therapy, which finally improves bioavailability of the therapeutic molecules in the inner ear.

个人简历：
　  邹静，男性。芬兰坦佩雷大学医院耳鼻咽喉科副教授（Experimental Otolaryngology），博士生导师；兼任上海第二军医大学附属长海医院耳鼻咽喉头颈外科主任医师、教授、博士生导师、耳科学带头人。